Institut de Recherches Internationales Servier
PharmaNeuilly-sur-Seine, France, France · Est. 1954 · 22,000 employees
Institut de Recherches Internationales Servier is a private French pharmaceutical company that develops and manufactures drugs across multiple therapeutic areas including cardiovascular disease, cancer, and immunological conditions.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
67
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 21
Phase 13
By Therapeutic Area
top 2
Oncology
480%
Neurology
120%
R&D Momentum
46/100
Pipeline Velocity
6/100
Trial Completion Rate
76/100
Pipeline Concentration
68/100
Pipeline Freshness
50/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Jun 30, 2026TrialA Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Nov 24, 2025TrialA First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
May 1, 2025TrialS095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Dec 16, 2024TrialIvosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Dec 3, 2024TrialIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Apr 25, 2024TrialPhase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
Apr 18, 2023TrialPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
4 more events
Mar 14, 2023TrialA Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
Jan 20, 2023TrialStudy of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Nov 21, 2022TrialImmuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
Apr 21, 2022TrialPhase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
Details
Company Info
Company Overview
—
Mkt Cap
$4.5B
Revenue
—
Cash
CEOOlivier Laureau
Founded1954
Employees22,000
HQNeuilly-sur-Seine, France, France
Websiteservier.com
LinkedInCompany Page
Therapeutic Focus
CardiovascularOncologyImmunologyGastroenterology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)